Granulocyte colony stimulating factor (G-CSF) has been recommended by the National Comprehensive Cancer Network (NCCN) 2 for dose dense regimens with a high likelihood of causing treatment-related neutropenia, such as the above mentioned anthracycline based regiments. The gene discussed is CSF3; the disease is Decreased total neutrophil count.